1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6039BF389EFDC18D9652580C100435FF7
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/determining-best-practices-data-dissemination-policies-global-field-medical-teams?opendocument
18
19opendocument
203.80.224.52
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Data Management and Biostatics

Determining Best Practices for Data Dissemination Policies for Global Field Medical Teams

ID: POP-279


Features:

4 Info Graphics

21 Data Graphics

100+ Metrics


Pages: 31


Published: 2017


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
With the shift toward evidence-based medicine and value-based pricing in the bio-pharmaceutical industry, organizations are turning to their Medical Affairs function to effectively streamline the dissemination of critical data. It is important for Medical Affairs leaders to formulate guidelines around on-label and off-label data discussions for global field medical teams to ensure compliance and consistency.


Best Practices, LLC undertook benchmarking research to provide a high-level understanding of organizational policies around data dissemination by field medical staff in North America, Europe, APAC and Emerging Markets.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbvie; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Gilead Sciences; Janssen; Novartis; Pfizer; Roche; Sanofi; Santen; Sunovion; Teva Pharmaceutical Industries Ltd


Study Snapshot

Best Practices, LLC engaged 18 leaders with direct experience working in the dissemination of scientific data to physicians and thought leaders from 13 leading bio-pharmaceutical companies. Nearly 70% of participants are at the level of director or above.

Key Findings

Major Data Shared Only On Request Before Label Change: In all markets, major data are shared only on request. Both in US and in Europe, nearly 40% participants disseminate data for safety information. However, in Europe, 25% of the companies release major data only if the information is off-label or inconsistent with the label while in APAC region, a quarter of the benchmark class disseminates safety information before label change.


Table of Contents

Executive Summarypgs. 4-7
Research Overviewpg. 4
Participating Companiespg. 5
Key Insightspgs. 6-7
Medical Data Disseminationpgs. 8-29
About Best Practices, LLCpgs. 30-31

    List of Charts & Exhibits

    • Approach on On-Label & Off-Label Field Medical Data Discussions in North America, Europe, APAC and Emerging Markets
    • Permission for Off-Label Data Discussions with HCPs in Each Market including North America, Europe, APAC and Emerging Markets
    • Restrictions on Off-Label Data Discussions in Each Market including North America, Europe, APAC and Emerging Markets
    • Dissemination of Major Data Releases Prior to Label Change in Each Market including North America, Europe, APAC and Emerging Markets
    • Approval of Data Dissemination in Each Market including North America, Europe, APAC and Emerging Markets